Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

$IDXGPress releaseOct 14, 2026, 8:29 PM ETRead the release

Interpace Biosciences pre-announced preliminary unaudited Q3 2026 revenue of $10.1-$10.4 million, up 15-18% year-over-year. That also represents 11-14% sequential growth from Q2 2026 revenue of $9.1 million, indicating accelerating demand for its thyroid molecular diagnostics.

Key figures

Revenue: $10.1 million to $10.4 million
Revenue Yoy: 15% to 18%
Qoq growth: 11% to 14%
Q2 2026 revenue: $9.1 million
Q3 2025 revenue: $8.8 million

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.